FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average b	ourden						
hours por rosponso	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses) 1. Name and Address of Reporting Person * Murugan Amar					2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Kast) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900				3. Date of Earliest Transaction (Month/Day/Year) 04/20/2020								X Officer (give title below) Other (specify below) SVP, GC & Secretary						
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person						
SOUTH SAN FRANCISCO, CA 94080 (City) (State) (Zip)				Table I. Non-Derivative Securities Acqui								ired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea		2A. Deemed Execution Date, if any (Month/Day/Year)		d Date, if	3. Transaction Code (Instr. 8)		ion 4. (/	4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5) (A) or Amount (D)		ired f (D)	5. Amoun Owned Fo	Amount of Securities Beneficially wned Following Reported ransaction(s) nstr. 3 and 4)		neficially (Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common S	Stock		04/20/2020				A		_	5,000	A		55,000)	
	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	(<i>e.g.</i> , pt	uts, c	5. Numb Derivati	rants, per of ve	opti 6. I Ex ₁	d, Dispoions, cor Date Exc piration	sed of, on vertible ercisable Date	r Benef	ficially (ties) 7. Title	and Amo		Derivative		Ownersl	nip of Indirec
Derivative Conversion Date		3A. Deemed Execution Date, if	4. Transac Code	5. Numb Derivati Securitie			Expiration Date of U (Month/Day/Year) Secu		7. Title of Und Securit	itle and Amount Jnderlying		8. Price of Derivative Security (Instr. 5)	Derivative					
	Derivative Security					or Disposed o (D) (Instr. 3, 4, and 5)										Owned Following Reported Transaction(s (Instr. 4)	Security Direct (I or Indirects) (I) (Instr. 4	O) ect
				Code	V	(A)	(D)		te ercisable	Expirat Date	tion	Title	Amo or Nun of S			(IIISU: 4)	(IIIsu. +	
Employee Stock Option (Right to Buy)	\$ 8.2	04/20/2020		A		110,00	0		(2)	04/19	/2030	Comm	1110	,000	\$ 0	110,000	D	
Report	ing Ov	vners																

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Murugan Amar C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO, CA 94080			SVP, GC & Secretary				

Signatures

/s/ David Tucker, Attorney-in-Fact	04/21/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) 25% of the shares subject to these restricted stock units ("RSUs") vest on May 15, 2021 and 1/16th of the total number shares subject to the RSUs vest on each of the next 12 Quarterly Vesting Dates (as defined below), subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year.
- (2) 25% of the shares subject to the option vest on April 20, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.